Alex Aliper, PhD, is the President of Insilico Medicine. He pioneered the application of AI in multi-omics data for drug discovery and drug repurposing, generative chemistry, and generative biology and put an AI-designed drug into human clinical trials. Alex built a team of over 100 AI engineers who developed state-of-the-art software products for target discovery, small molecule generation, and clinical trial outcome prediction.